Cargando…
Common transcriptional signatures of neuropathic pain
The dorsal root ganglia (DRG) are key structures in nociception and chronic pain disorders. Several gene expression studies of DRG in preclinical pain models have been performed, but it is unclear if consistent gene changes are identifiable. We, therefore, compared several recent RNA-Seq data sets o...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302324/ https://www.ncbi.nlm.nih.gov/pubmed/32107361 http://dx.doi.org/10.1097/j.pain.0000000000001847 |
_version_ | 1783547821770670080 |
---|---|
author | Pokhilko, Alexandra Nash, Anthony Cader, M. Zameel |
author_facet | Pokhilko, Alexandra Nash, Anthony Cader, M. Zameel |
author_sort | Pokhilko, Alexandra |
collection | PubMed |
description | The dorsal root ganglia (DRG) are key structures in nociception and chronic pain disorders. Several gene expression studies of DRG in preclinical pain models have been performed, but it is unclear if consistent gene changes are identifiable. We, therefore, compared several recent RNA-Seq data sets on the whole DRG in rodent models of nerve injury. Contrary to previous findings, we show hundreds of common differentially expressed genes and high positive correlation between studies, despite model and species differences. We also find, in contrast to previous studies, that 60% of the common rodent gene response after injury is likely to occur in nociceptors of the DRG. Substantial expression changes are observed at a 1-week time-point, with smaller changes in the same genes at a later 3- to 4-week time-point. However, a subset of genes shows a similar magnitude of changes at both early and late time-points, suggesting their potential involvement in the maintenance of chronic pain. These genes are centred around suppression of endogenous opioid signalling. Reversal of this suppression could allow endogenous and exogenous opioids to exert their analgesic functions and may be an important strategy for treating chronic pain disorders. Currently used drugs, such as amitriptyline and duloxetine, do not seem to appropriately modulate many of the critical pain genes and indeed may transcriptionally suppress endogenous opioid signalling further. |
format | Online Article Text |
id | pubmed-7302324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-73023242020-06-29 Common transcriptional signatures of neuropathic pain Pokhilko, Alexandra Nash, Anthony Cader, M. Zameel Pain Research Paper The dorsal root ganglia (DRG) are key structures in nociception and chronic pain disorders. Several gene expression studies of DRG in preclinical pain models have been performed, but it is unclear if consistent gene changes are identifiable. We, therefore, compared several recent RNA-Seq data sets on the whole DRG in rodent models of nerve injury. Contrary to previous findings, we show hundreds of common differentially expressed genes and high positive correlation between studies, despite model and species differences. We also find, in contrast to previous studies, that 60% of the common rodent gene response after injury is likely to occur in nociceptors of the DRG. Substantial expression changes are observed at a 1-week time-point, with smaller changes in the same genes at a later 3- to 4-week time-point. However, a subset of genes shows a similar magnitude of changes at both early and late time-points, suggesting their potential involvement in the maintenance of chronic pain. These genes are centred around suppression of endogenous opioid signalling. Reversal of this suppression could allow endogenous and exogenous opioids to exert their analgesic functions and may be an important strategy for treating chronic pain disorders. Currently used drugs, such as amitriptyline and duloxetine, do not seem to appropriately modulate many of the critical pain genes and indeed may transcriptionally suppress endogenous opioid signalling further. Wolters Kluwer 2020-07 2020-02-26 /pmc/articles/PMC7302324/ /pubmed/32107361 http://dx.doi.org/10.1097/j.pain.0000000000001847 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Research Paper Pokhilko, Alexandra Nash, Anthony Cader, M. Zameel Common transcriptional signatures of neuropathic pain |
title | Common transcriptional signatures of neuropathic pain |
title_full | Common transcriptional signatures of neuropathic pain |
title_fullStr | Common transcriptional signatures of neuropathic pain |
title_full_unstemmed | Common transcriptional signatures of neuropathic pain |
title_short | Common transcriptional signatures of neuropathic pain |
title_sort | common transcriptional signatures of neuropathic pain |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302324/ https://www.ncbi.nlm.nih.gov/pubmed/32107361 http://dx.doi.org/10.1097/j.pain.0000000000001847 |
work_keys_str_mv | AT pokhilkoalexandra commontranscriptionalsignaturesofneuropathicpain AT nashanthony commontranscriptionalsignaturesofneuropathicpain AT cadermzameel commontranscriptionalsignaturesofneuropathicpain |